• Over 30 years of academic and professional focus on Chemical and Biomedical Engineering. Technion, Massachusetts Institute of Technology, Oxford University, Harvard Medical School, UCLA.

• Over 20 years of experience in financial markets focused on Life Sciences. Wall Street Journal's "Best on the Street" award recipient.

 

Dr. Fariba Ghodsian is the Chief Investment Officer of DAFNA Capital Management.

 

Dr. Ghodsian completed her postdoctoral fellowship in protein modeling at Harvard Medical School. She received her D. Phil. in Biomedical Engineering from Oxford University in England, M.S. in Chemical Engineering from Massachusetts Institute of Technology, MBA from the University of California at Los Angeles, and B.S. in Chemical Engineering from Technion, Israel Institute of Technology.

 

Prior to joining the firm in 2002, Dr. Ghodsian was Managing Director of Healthcare Research at Roth Capital Partners. Before this, she was a senior biotechnology analyst at Lehman Brothers, Hancock Institutional, and Wedbush Morgan Securities, as well as Director of Business Development at Medclone and a research scientist at Allergan Pharmaceuticals.

 

In 2002, Dr. Ghodsian received the Wall Street Journal's "Best on the Street" award, as one of the top five biotechnology analysts. In 2015, she was profiled in the book “Women of the Street: Why Female Money Managers Generate Higher Returns”. She has been a frequent guest speaker at conferences, has authored multiple scientific publications, holds several patents, and has served on the NIH's Scientific Grant Review Board. She is involved with several non-profit organizations and currently serves on the board and investment committee of the American Technion Society.

 

Click on the following to access a list of Dr. Ghodsian's Scientific and Financial Publications, Presentations, Patents, and Honors and Awards.